J. Christopher Naftzger

Insider Reports History

Location
Lewisberry, PA
Signature
/s/ David C. Hastings as attorney-in-fact for J. Christopher Naftzger
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by J. Christopher Naftzger:

Company Role Class Num Shares Value Price $ Report Date Ownership
Arbutus Biopharma Corp General Counsel and CCO Stock Option (Right to Buy) 220,300 $1,069,205 $2.81 14 Feb 2025 Direct
Arbutus Biopharma Corp General Counsel and CCO Common Shares 140,544 $461,406 $3.28 14 Feb 2025 Direct
Nabriva Therapeutics plc General Counsel and Corp Sec Ordinary Shares 7,000 $10,500 $1.50 27 Dec 2021 Direct
Nabriva Therapeutics plc General Counsel and Corp Sec Share Option 100,000 30 Sep 2021 Direct
Nabriva Therapeutics plc General Counsel and Corp Sec Stock Appreciation Right 63,200 11 Aug 2022 Direct
Nabriva Therapeutics plc General Counsel and Corp Sec Phantom Shares 31,600 11 Aug 2022 Direct
Nabriva Therapeutics plc General Counsel and Corp Sec Restricted Stock Units 0 11 Aug 2022 Direct
Nabriva Therapeutics plc General Counsel and Corp Sec Share Options 0 11 Aug 2022 Direct

Insider Reports Filed by J. Christopher Naftzger

Symbol Company Period Transactions Value $ Form Type Role Filing Time
ABUS Arbutus Biopharma Corp 14 Feb 2025 2 $0 4 General Counsel and CCO 19 Feb 2025, 18:25
ABUS Arbutus Biopharma Corp 04 Feb 2025 1 -$37,206 4 General Counsel and CCO 05 Feb 2025, 16:02
ABUS Arbutus Biopharma Corp 01 Feb 2024 2 $0 4 General Counsel and CCO 05 Feb 2024, 19:55
ABUS Arbutus Biopharma Corp 10 Jul 2023 1 $0 4 General Counsel and CCO 12 Jul 2023, 16:12
ABUS Arbutus Biopharma Corp 10 Jul 2023 0 $0 3 General Counsel and CCO 12 Jul 2023, 16:10
/report/000110465922091488-naftzger-j-christopher-2022-08-11 Nabriva Therapeutics plc 11 Aug 2022 4 $0 4 General Counsel and Corp Sec 15 Aug 2022, 20:39
/report/000110465921154012-naftzger-j-christopher-2021-12-27 Nabriva Therapeutics plc 27 Dec 2021 1 +$4,130 4 General Counsel and Corp Sec 28 Dec 2021, 18:04
/report/000110465921121964-naftzger-j-christopher-2021-09-30 Nabriva Therapeutics plc 30 Sep 2021 1 $0 4 General Counsel and Corp Sec 01 Oct 2021, 16:06
/report/000110465921116068-naftzger-j-christopher-2021-09-03 Nabriva Therapeutics plc 03 Sep 2021 0 $0 3 General Counsel and Corp Sec 15 Sep 2021, 20:36
/report/000110465922010484-naftzger-j-christopher-2021-01-28 Nabriva Therapeutics plc 28 Jan 2021 2 $0 4 General Counsel and Corp Sec 01 Feb 2022, 17:35